These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 581876)

  • 1. Correlation between thyroid stimulators and 3,5,3'-triiodothyronine suppressibility in patients during treatment for hyperthyroidism with thionamide drugs: comparison of assays by thyroid-stimulating and thyrotropin-displacing activities.
    Kuzuya N; Chiu SC; Ikeda H; Uchimura H; Ito K; Nagataki S
    J Clin Endocrinol Metab; 1979 Apr; 48(4):706-11. PubMed ID: 581876
    [No Abstract]   [Full Text] [Related]  

  • 2. Dissociation of serum LATS content and thyroid suppressibility during treatment of hyperthyroidism.
    Chopra IJ; Solomon DH; Johnson DE; Chopra U; Fischer DA
    J Clin Endocrinol Metab; 1970 Apr; 30(4):524-8. PubMed ID: 5435290
    [No Abstract]   [Full Text] [Related]  

  • 3. Similar effects of thionamide drugs and perchlorate on thyroid-stimulating immunoglobulins in Graves' disease: evidence against an immunosuppressive action of thionamide drugs.
    Wenzel KW; Lente JR
    J Clin Endocrinol Metab; 1984 Jan; 58(1):62-9. PubMed ID: 6196375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of long-acting thyroid stimulator with serum levels of tri-iodothyronine, thyroxine and thyrotropin in Graves' disease.
    Sawhney RC; Kannan V; Rastogi GK
    J Assoc Physicians India; 1975 Feb; 23(2):111-4. PubMed ID: 1242389
    [No Abstract]   [Full Text] [Related]  

  • 5. Inappropriate suppression of thyrotropin during medical treatment of Graves disease in childhood.
    Sills IN; Horlick MN; Rapaport R
    J Pediatr; 1992 Aug; 121(2):206-9. PubMed ID: 1640284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dissociation of responsiveness to thyrotropin-releasing hormone and thyroid suppressibility following antithyroid drug therapy of hyperthyroidism.
    Martino E; Pinchera A; Capiferri R; Macchia E; Sardano G; Bartalena L; Mazzanti F; Baschieri L
    J Clin Endocrinol Metab; 1976 Sep; 43(3):543-9. PubMed ID: 821960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thyroid gland in Graves' disease: victim or culprit?
    Chopra IJ; Solomon DH; Johnson DE; Chopra U
    Metabolism; 1970 Oct; 19(10):760-72. PubMed ID: 5535910
    [No Abstract]   [Full Text] [Related]  

  • 8. The long-acting thyroid stimulatory: is it of importance in Graves' disease.
    McKenzie JM; Zakarija M; D'Amour P; Joasoo A
    N Z Med J; 1975 Jan; 81(531):18-21. PubMed ID: 165442
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparison of single daily dose of methimazole and propylthiouracil in the treatment of Graves' hyperthyroidism.
    He CT; Hsieh AT; Pei D; Hung YJ; Wu LY; Yang TC; Lian WC; Huang WS; Kuo SW
    Clin Endocrinol (Oxf); 2004 Jun; 60(6):676-81. PubMed ID: 15163329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppressibility of thyroid function despite high levels of long-acting thyroid stimulator.
    Wong ET; Doe RP
    Ann Intern Med; 1972 Jan; 76(1):77-84. PubMed ID: 4112158
    [No Abstract]   [Full Text] [Related]  

  • 11. The relationship of thyroxine turnover to other parameters of peripheral thyroid function in Graves' disease.
    Clifton-Bligh P; Burke G
    J Lab Clin Med; 1975 Jun; 85(6):922-33. PubMed ID: 48532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thionamide therapy in Graves' disease: relation of relapse rate to duration of therapy.
    Tamai H; Nakagawa T; Fukino O; Ohsako N; Shinzato R; Suematsu H; Kuma K; Matsuzuka F; Nagataki S
    Ann Intern Med; 1980 Apr; 92(4):488-90. PubMed ID: 6892672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absence of thyroid-stimulating antibody and long acting thyroid stimulator in relatives of Graves' disease patients.
    Banovac K; Zakarija M; McKenzie JM; Witte A; Sekso M
    J Clin Endocrinol Metab; 1981 Sep; 53(3):651-3. PubMed ID: 6790561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abnormalities of hypothalamo-hypophyseal-thyroid axis in patients with Graves' ophthalmopathy.
    Chopra IJ; Chopra U; Orgiazzi J
    J Clin Endocrinol Metab; 1973 Dec; 37(6):955-67. PubMed ID: 4201831
    [No Abstract]   [Full Text] [Related]  

  • 15. Relationships among immunoglobulin markers in Graves' disease.
    Ozawa Y; Maciel RM; Chopra IJ; Solomon DH; Beall GN
    J Clin Endocrinol Metab; 1979 Mar; 48(3):381-7. PubMed ID: 581874
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparison of effects of high and low dosage regimens of antithyroid drugs in the management of Graves' hyperthyroidism.
    Romaldini JH; Bromberg N; Werner RS; Tanaka LM; Rodrigues HF; Werner MC; Farah CS; Reis LC
    J Clin Endocrinol Metab; 1983 Sep; 57(3):563-70. PubMed ID: 6192139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triiodothyronine toxicosis developing during antithyroid drug therapy for hyperthyroidism.
    Hollander CS; Shenkman L; Mitsuma T; Asper SP
    Johns Hopkins Med J; 1972 Aug; 131(2):184-8. PubMed ID: 5068365
    [No Abstract]   [Full Text] [Related]  

  • 18. Absence of thyroid-binding immunoglobulins in patients with thyrotropin-mediated hyperthyroidism.
    Kourides IA; Pekonen F; Weintraub BD
    J Clin Endocrinol Metab; 1980 Aug; 51(2):272-4. PubMed ID: 6105164
    [No Abstract]   [Full Text] [Related]  

  • 19. Value of simultaneous T3, T4, and TSH measurements for management of graves' disease in children.
    Golden MP; Kaplan SA; Lippe BM; Lee WN
    Pediatrics; 1977 May; 59(5):762-7. PubMed ID: 577011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Laboratory tests for evaluating thyroid therapy.
    Kabadi UM
    Am Fam Physician; 1982 Sep; 26(3):183-8. PubMed ID: 6180620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.